NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
Eli Lilly and Company
CellCentric Ltd.
Ohio State University Comprehensive Cancer Center
Aprea Therapeutics
Hoffmann-La Roche
TG Therapeutics, Inc.
AbbVie
Hoffmann-La Roche